Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTPRZ1-targeted CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Université de Genève
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
PTPRZ1-targeted CAR-T cells are an experimental cellular immunotherapy being developed for the treatment of glioblastoma (GBM). The therapy targets Protein Tyrosine Phosphatase Receptor Type Z1 (PTPRZ1), a surface antigen that is highly enriched in malignant glioma tissues, including glioma stem cells and various differentiation trajectories, while maintaining minimal expression in normal adult brain tissue. Developed through an integrated pipeline involving single-nucleus RNA sequencing and generative AI-driven antibody design, these CAR-T cells are engineered with TCR-mimetic architectures and modular costimulatory domains. This design aims to achieve high antigen sensitivity, improved functional persistence, and resistance to the immunosuppressive tumor microenvironment, addressing the challenges of intratumoral heterogeneity and cellular plasticity in GBM.
- Other names
- CAR T cells targeting PTPRZ1PTPRZ1 CAR-TPTPRZ-1 CAR-TPTPRZ 1 CAR-TPTPRZ1-directed CAR-T cellsPTPRZ-1-directed CAR-T cellsPTPRZ 1-directed CAR-T cells
02
Targets
PTPRZ1 (Protein tyrosine phosphatase receptor type Z1)
Beyond the preview
Go deeper on PTPRZ1-targeted CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTPRZ1-targeted CAR-T cells.